Triglycerides, Medium-Chain
drugOn this page
Also known as Medium chain triglyceridesMedium-chain triglyceridesTriglyceridesmedium-chain
Summary
Triglycerides, Medium-Chain (CHEMBL2108659) is an approved unknown targeting FFAR1, TRPA1, and KCNK10; indicated across 1 condition including heart failure.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- Targets: 4 (FFAR1, TRPA1, KCNK10…)
- Indications: 1 condition
- Clinical trials: 10
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108659 |
| Name | Triglycerides, Medium-Chain |
| Type | Unknown |
| Max phase | 4 |
Also known as: Medium chain triglycerides, Medium-chain triglycerides, Triglycerides, medium-chain, TRIGLYCERIDES, MEDIUM-CHAIN
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| FFAR1 | FFA1 receptor | Full agonist | 6 | 0.4% | O14842 |
| TRPA1 | TRPA1 | Activation | 4.4 | 0.1% | O75762 |
| KCNK10 | K2P10.1 | 0% | P57789 | ||
| RXRA | Retinoid X receptor-α | Agonist | 5.1% | P19793 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 4 target gene(s): FFAR1, TRPA1, KCNK10, RXRA.
Top Reactome pathways
79 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Neuronal System | 1 | KCNK10 |
| Developmental Biology | 1 | RXRA |
| Potassium Channels | 1 | KCNK10 |
| Tandem pore domain potassium channels | 1 | KCNK10 |
| TWIK related potassium channel (TREK) | 1 | KCNK10 |
| R-HSA-1368082 | 1 | RXRA |
| BMAL1:CLOCK,NPAS2 activates circadian expression | 1 | RXRA |
| Metabolism | 1 | RXRA |
| Mitochondrial biogenesis | 1 | RXRA |
| Recycling of bile acids and salts | 1 | RXRA |
| Signal Transduction | 1 | RXRA |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 1 | RXRA |
| Organelle biogenesis and maintenance | 1 | RXRA |
| Synthesis of bile acids and bile salts | 1 | RXRA |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 1 | RXRA |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 1 | RXRA |
| Bile acid and bile salt metabolism | 1 | RXRA |
| PPARA activates gene expression | 1 | RXRA |
| Carnitine shuttle | 1 | RXRA |
| Biological oxidations | 1 | RXRA |
| Cytochrome P450 - arranged by substrate type | 1 | RXRA |
| Phase I - Functionalization of compounds | 1 | RXRA |
| Endogenous sterols | 1 | RXRA |
| Epigenetic regulation of gene expression | 1 | RXRA |
| Generic Transcription Pathway | 1 | RXRA |
| Transcriptional activation of mitochondrial biogenesis | 1 | RXRA |
| Cellular responses to stress | 1 | RXRA |
| Activation of gene expression by SREBF (SREBP) | 1 | RXRA |
| SUMOylation | 1 | RXRA |
| SUMO E3 ligases SUMOylate target proteins | 1 | RXRA |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| signal transduction | 2 |
| monoatomic ion transport | 2 |
| monoatomic ion transmembrane transport | 2 |
| G protein-coupled receptor signaling pathway | 1 |
| phospholipase C-activating G protein-coupled receptor signaling pathway | 1 |
| positive regulation of cytosolic calcium ion concentration | 1 |
| insulin secretion | 1 |
| positive regulation of insulin secretion | 1 |
| negative regulation of interleukin-1 beta production | 1 |
| glucose homeostasis | 1 |
| positive regulation of calcium ion transport | 1 |
| response to fatty acid | 1 |
| ligand-gated ion channel signaling pathway | 1 |
| intracellular calcium ion homeostasis | 1 |
| cell surface receptor signaling pathway | 1 |
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| heart failure | 3 | MONDO:0005252 | EFO:0003144 |
Clinical trials
Total trials: 10.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 7 |
| PHASE4 | 1 |
| PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00672763 | PHASE4 | WITHDRAWN | Adjuvant Vitamin D With Corticosteroids in Active Crohn’s Disease |
| NCT00644098 | PHASE2 | COMPLETED | Effect of a Soluble Fibre Blend and Medium Chain Triglycerides on Body Composition and Cardiometabolic Risk Factors |
| NCT01252979 | EARLY_PHASE1 | COMPLETED | Ketones & Mitochondrial Heteroplasmy |
| NCT01315171 | Not specified | COMPLETED | Effect of a Medium Chain Triglyceride Supplemented Diet on Cognitive Function and Brain Activation in Type 1 Diabetes. |
| NCT01806142 | Not specified | COMPLETED | Effects of Medium-Chain Triglycerides on Chylomicron Secretion and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With Dyslipidemia Associated With the Metabolic Syndrome |
| NCT02199821 | Not specified | COMPLETED | Inflammatory Response With Different Lipid Emulsions In Parenteral Nutrition In Children After Bone Marrow Transplantation |
| NCT02248948 | Not specified | COMPLETED | Superiority of Omega-3 Versus Placebo on the Improvement of ADHD in Children |
| NCT03610477 | Not specified | COMPLETED | MiCrobiome dieT Study |
| NCT05779410 | Not specified | COMPLETED | Vitamin D in Healthy Adults After Strenuous Endurance Exercise |
| NCT05781620 | Not specified | UNKNOWN | Vitamin D Supplementation in Healthy Adults in Prolonged Endurance Exercise |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
52 molecules share ≥1 primary target. Top 52 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| DOCONEXENT | ChEMBL + PubChem | Phase 3 (approved) | FFAR1, KCNK10, RXRA |
| ROSIGLITAZONE | ChEMBL | Phase 4 (approved) | FFAR1, RXRA |
| CARVEDILOL | ChEMBL + PubChem | Phase 4 (approved) | KCNK10 |
| DICLOFENAC | ChEMBL + PubChem | Phase 4 (approved) | TRPA1 |
| DISULFIRAM | ChEMBL + PubChem | Phase 4 (approved) | TRPA1 |
| MEFENAMIC ACID | ChEMBL + PubChem | Phase 4 (approved) | TRPA1 |
| SULINDAC | ChEMBL + PubChem | Phase 4 (approved) | RXRA |
| ALITRETINOIN | ChEMBL | Phase 4 (approved) | RXRA |
| BEXAROTENE | ChEMBL | Phase 4 (approved) | RXRA |
| CALCITRIOL | ChEMBL | Phase 4 (approved) | RXRA |
| DOMPERIDONE | ChEMBL | Phase 4 (approved) | RXRA |
| FLUVASTATIN | ChEMBL | Phase 4 (approved) | RXRA |
| LEVOTHYROXINE | ChEMBL | Phase 4 (approved) | RXRA |
| MECLOFENAMIC ACID | ChEMBL | Phase 4 (approved) | RXRA |
| MENTHOL | ChEMBL | Phase 4 (approved) | TRPA1 |
| NICOTINE | ChEMBL | Phase 4 (approved) | TRPA1 |
| OXAPROZIN | ChEMBL | Phase 4 (approved) | RXRA |
| PIOGLITAZONE | ChEMBL | Phase 4 (approved) | RXRA |
| PITAVASTATIN | ChEMBL | Phase 4 (approved) | RXRA |
| TRETINOIN | ChEMBL | Phase 4 (approved) | RXRA |
| RESVERATROL | ChEMBL + PubChem | Phase 3 (approved) | TRPA1 |
| CANNABINOL | ChEMBL | Phase 3 | TRPA1 |
| FASIGLIFAM | ChEMBL | Phase 3 | FFAR1 |
| GAMOLENIC ACID | ChEMBL | Phase 3 | FFAR1 |
| ICILLIN | ChEMBL | Phase 3 | TRPA1 |
| ICOSAPENT | ChEMBL | Phase 3 | RXRA |
| LEVOMENTHOL | ChEMBL | Phase 3 | TRPA1 |
| TIRATRICOL | ChEMBL | Phase 3 | RXRA |
| ALLICIN | ChEMBL | Phase 2 | TRPA1 |
| CANNABIDIVARIN | ChEMBL | Phase 2 | TRPA1 |
| CANNABIGEROL | ChEMBL | Phase 2 | TRPA1 |
| CARVACROL | ChEMBL | Phase 2 | TRPA1 |
| CHLORDANTOIN | ChEMBL | Phase 2 | TRPA1 |
| FENBUFEN | ChEMBL | Phase 2 | FFAR1 |
| FLUFENAMIC ACID | ChEMBL | Phase 2 | TRPA1 |
| IRX-4204 | ChEMBL | Phase 2 | RXRA |
| LINOLEIC ACID | ChEMBL | Phase 2 | FFAR1 |
| PIRINIXIC ACID | ChEMBL | Phase 2 | RXRA |
| RG6341 | ChEMBL | Phase 2 | TRPA1 |
| SALIRASIB | ChEMBL | Phase 2 | TRPA1 |
| SANGUINARIUM | ChEMBL | Phase 2 | TRPA1 |
| TETRAHYDROCANNABIVARIN | ChEMBL | Phase 2 | TRPA1 |
| THYMOL | ChEMBL | Phase 2 | TRPA1 |
| Acetaldehyde | PubChem | Approved | TRPA1 |
| Berberine Chloride | PubChem | Approved | RXRA |
| Caffeine | PubChem | Approved | TRPA1 |
| camphor (synthetic) | PubChem | Approved | TRPA1 |
| dronabinol | PubChem | Approved | TRPA1 |
| Eugenol | PubChem | Approved | TRPA1 |
| Ezetimibe | PubChem | Approved | RXRA |
| menthol, unspecified form | PubChem | Approved | TRPA1 |
| Propylene Glycol | PubChem | Approved | TRPA1 |
Related Atlas pages
- Genes: FFAR1, TRPA1, KCNK10, RXRA
- Diseases: heart failure
- Drugs: Doconexent, Rosiglitazone, Carvedilol, Diclofenac, Disulfiram, Mefenamic Acid, Sulindac, Alitretinoin, Bexarotene, Calcitriol, Domperidone, Fluvastatin, Levothyroxine, Meclofenamic Acid, Menthol, Nicotine, Oxaprozin, Pioglitazone, Pitavastatin, Tretinoin, Resveratrol, Cannabinol, Fasiglifam, Gamolenic Acid, Icillin, Icosapent, Tiratricol, Berberine Chloride, Caffeine, camphor (synthetic), dronabinol, Ezetimibe, Propylene Glycol